Bryan Steadman is the Chief Technical Officer of VitriVax. He is an experienced biopharmaceutical executive, team builder and scientist. Prior to joining VitriVax, Bryan built the CMC and Quality organizations for two startups (Universal Cells and LigoCyte) that were acquired by large pharma. Throughout his 30-year career in both large and small pharma companies, Bryan has developed a reputation for finding phase appropriate solutions to technical issues and bridging the gaps between academic research, product development and strategic goals. As the Executive Director Process Development at Amgen, he was instrumental in pulling together Manufacturing of the Future technologies and suppliers to leverage disposable technologies for commercial antibody production. Working at Allergan, Bryan built the process development team for botulinum neurotoxin development. Bryan has also served as Director of Strategic Planning and Portfolio Management for Bristol Myers Squibb and facilitated CMC Technology Road mapping processes. Bryan earned his BS in Microbiology, PhD in Environmental Toxicology, and postdoc as a Biophysical chemist. He started his pharmaceutical career as a bench scientist working on protein and vaccine formulation at Merck.